Aripiprazole is indicated for the treatment of schizophrenia in individuals aged 13 years and older, including maintenance treatment; for monotherapy or adjunctive therapy in the treatment of acute manic or mixed episodes associated with bipolar I disorder in patients aged 10 years and older; for maintenance treatment of bipolar I disorder as monotherapy or in combination with other medications; as adjunctive therapy in major depressive disorder; and for the treatment of irritability associated with autistic disorder in pediatric patients aged 6 to 17 years. The intramuscular formulation is used for the management of acute agitation associated with schizophrenia or bipolar I disorder. Additionally, aripiprazole is sometimes used off-label for other psychiatric conditions such as delusional disorder, behavioral disturbances associated with dementia, childhood and adolescent behavioral disorders, and impulse control disorders. In China, its approved indication is limited to schizophrenia.